"Leucovorin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS.
| Descriptor ID |
D002955
|
| MeSH Number(s) |
D03.633.100.733.631.400.800.350.450 D08.211.840.300.500
|
| Concept/Terms |
Leucovorin- Leucovorin
- Folinic Acid-SF
- Folinic Acid SF
- Leukovorin
- Leukovorum
- Folinic Acid
- Acid, Folinic
Citrovorum Factor- Citrovorum Factor
- Factor, Citrovorum
- Calcium Leucovorin
- Leucovorin, Calcium
- Calcium Folinate
- Folinate, Calcium
N(5)-Formyltetrahydrofolate- N(5)-Formyltetrahydrofolate
- 5-Formyltetrahydropteroylglutamate
- 5 Formyltetrahydropteroylglutamate
- 5-Formyltetrahydrofolate
- 5 Formyltetrahydrofolate
|
Below are MeSH descriptors whose meaning is more general than "Leucovorin".
Below are MeSH descriptors whose meaning is more specific than "Leucovorin".
This graph shows the total number of publications written about "Leucovorin" by people in this website by year, and whether "Leucovorin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 2 | 3 |
| 2017 | 1 | 11 | 12 |
| 2018 | 0 | 9 | 9 |
| 2019 | 0 | 4 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Leucovorin" by people in Profiles.
-
Do clinical trials change practice? A longitudinal, international assessment of colorectal cancer prescribing practices. Cancer Treat Res Commun. 2021; 28:100445.
-
Molecular docking and simulation studies on SARS-CoV-2 Mpro reveals Mitoxantrone, Leucovorin, Birinapant, and Dynasore as potent drugs against COVID-19. J Biomol Struct Dyn. 2021 11; 39(18):7294-7305.
-
Challenges of pancreatic cancer chemotherapy in the COVID-19 era. J Gastrointestin Liver Dis. 2020 06 04; 29(2):273-275.
-
Part II. high-dose methotrexate with leucovorin rescue for severe COVID-19: An immune stabilization strategy for SARS-CoV-2 induced 'PANIC' attack. J Neurol Sci. 2020 08 15; 415:116935.
-
Hepatic arterial chemotherapy for hepatocellular carcinoma. Lancet Oncol. 2019 06; 20(6):e301.
-
Transcriptome Alterations in Liver Metastases of Colorectal Cancer After Acquired Resistance to Cetuximab. Cancer Genomics Proteomics. 2019 May-Jun; 16(3):207-219.
-
Cytoplasmic E-Cadherin Expression Is Associated With Higher Tumour Level of VEGFA, Lower Response Rate to Irinotecan-based Treatment and Poorer Prognosis in Patients With Metastatic Colorectal Cancer. Anticancer Res. 2019 Apr; 39(4):1953-1957.
-
FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data. Clin Colorectal Cancer. 2019 06; 18(2):133-140.
-
Rapidly progressing ulcer and a urine drainage bag. Dermatol Online J. 2018 Nov 15; 24(11).
-
Patients with hMLH1 or/and hMSH2-deficient Metastatic Colorectal Cancer Are Associated with Reduced Levels of Vascular Endothelial Growth Factor-1 Expression and Higher Response Rate to Irinotecan-based Regimen. Anticancer Res. 2018 Nov; 38(11):6399-6404.